Search clinical trials for: BRAF mutant melanoma

Total 4400 results

Southwest Oncology Group
National Cancer Institute (NCI); Roche-Genentech

Completed

S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Colorectal Cancer

United States
Pfizer

Completed

A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma

Locally Advanced or Metastatic NRAS Mutant Melanoma

United States, Australia, Germany, Italy, Netherlands
Array Biopharma, now a wholly owned subsidiary...

Withdrawn

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

Non-Small Cell Lung Cancer

United States
Prof. Dr. med. Dirk Schadendorf
Boehringer Ingelheim; medac GmbH; Alcedis GmbH

Completed

Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma (NIPAWILMA)

Cutaneous Malignant Melanoma

Germany
Prof. Dr. med. Dirk Schadendorf

Terminated

Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma (BOTTOM)

Malignant Melanoma

Germany
NYU Langone Health
AstraZeneca

Completed

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
West Cancer Center
Amgen; University of Tennessee Health Science Center

Unknown

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

Melanoma | BRAF Gene Mutation

United States
Philip Friedlander
Genentech, Inc.

Terminated

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

Melanoma

United States
Hanmi Pharmaceutical Company Limited

Completed

Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers

Solid Tumor

Korea, Republic of
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Recurrent Melanoma | Stage IV Melanoma

United States
Genentech, Inc.

Completed

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Malignant Melanoma

United States
M.D. Anderson Cancer Center

Completed

Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer

Solid Tumor | Advanced Cancer

United States
Daiichi Sankyo, Inc.
Plexxikon

Terminated

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

V600-mutated BRAF Unresectable Melanoma | V600-mutated BRAF Metastatic Melanoma | Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor

United States, Germany, France
Memorial Sloan Kettering Cancer Center
Novartis; National Comprehensive Cancer Network

Completed

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

Melanoma

United States
Inge Marie Svane

Completed

Vemurafenib and TIL Therapy for Metastatic Melanoma

Metastatic Melanoma

Denmark
Grupo Español Multidisciplinar de Melanoma
Roche Farma, S.A; Pivotal S.L.

Completed

Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma

Melanoma

Spain
Adil Daud
National Comprehensive Cancer Network

Completed

Trametinib With GSK2141795 in BRAF Wild-type Melanoma

Melanoma

United States
Genentech, Inc.

Completed

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Metastatic Melanoma, BRAF V600 Mutation Positive

Korea, Republic of, Russian Federation, Israel, United States
Tocagen Inc.

Terminated

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Melanoma | Sarcoma | Lymphoma | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Bladder Cancer | Triple Negative Breast Cancer | IDH1 Mutated Solid Tumors | IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)

United States
Fudan University

Unknown

Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma (FU-Name-T001)

Melanoma Stage IIIB-IV

China
University of California, San Francisco

Terminated

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

ALK Fusion Protein Expression | Stage III Cutaneous Melanoma | Stage IIIA Cutaneous Melanoma | Stage IIIB Cutaneous Melanoma | Stage IIIC Cutaneous Melanoma | Stage IV Cutaneous Melanoma | ROS1 Fusion Positive | BRAF wt Allele | Invasive Skin Melanoma | MET Fusion Gene Positive | NRAS wt Allele | NTRK1 Fusion... and other conditions

United States
Center Eugene Marquis

Completed

Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis (CONVERCE)

Malignant Melanoma

France
Immunovative Therapies, Ltd.

Completed

AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer

Colorectal Cancer Metastatic

United States
Hoffmann-La Roche

Completed

An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma

Malignant Melanoma

South Africa
Yale University
National Cancer Institute (NCI)

Completed

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Celgene

Terminated

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Neoplasm Metastasis

United States, Australia
Hoffmann-La Roche

Completed

A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma

Metastatic Melanoma

Belgium, Poland
Walter J. Storkus
National Cancer Institute (NCI)

Completed

Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma

Metastatic Melanoma

United States
Hoffmann-La Roche

Completed

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

Malignant Melanoma

United States, Australia
Novartis Pharmaceuticals

Completed

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

Cancer

United States, Australia
Hoffmann-La Roche

Completed

A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Malignant Melanoma

China
M.D. Anderson Cancer Center

Completed

Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor

Melanoma

United States
Novartis Pharmaceuticals

Completed

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Melanoma and Brain Metastases

Canada, United States, Australia, France, Germany, Italy, Spain
MedImmune LLC

Completed

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Melanoma

Italy, United States, Canada, France
GlaxoSmithKline

Terminated

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Melanoma

Spain, France
Duke University

Withdrawn

A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma

Melanoma

United States
Universitair Ziekenhuis Brussel

Completed

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

Malignant Melanoma

Belgium
Hoffmann-La Roche

Completed

A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU]) (MELANIS)

Melanoma

France
The Netherlands Cancer Institute

Unknown

HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

Melanoma | Skin Neoplasms

Netherlands
Mohammed M Milhem
Genentech, Inc.

Terminated

Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib (ML28604)

Melanoma | Metastatic Melanoma | BRAF-mutated Metastatic Melanoma | V600EBRAF-mutated Metastatic Melanoma

United States
GlaxoSmithKline

Terminated

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

Melanoma and Brain Metastases

United States, Australia
Bristol-Myers Squibb

Completed

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Melanoma

United States
Hoffmann-La Roche

Completed

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

Malignant Melanoma

Italy, United Kingdom, Belgium, Poland, Netherlands, Germany, Austria, Czechia, Ireland, Sweden
Poitiers University Hospital

Completed

Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK (SVALMEL)

Unresecable Stage IIIc or IV Melanoma

France
University of Texas Southwestern Medical Center

Completed

A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma

Melanoma

United States
Centre Hospitalier Universitaire de Nice

Unknown

Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT ) (MALT)

Malignant Melanoma Stage III | Malignant Melanoma Stage IV
University of California, San Francisco
GlaxoSmithKline

Terminated

Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets

BRAFV600E Melanoma Patients

United States
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma

United States, Sweden, Australia, France, Italy, South Africa, Spain, United Kingdom, Germany, Netherlands, Israel, New Zealand, Belgium, Switzerland
GlaxoSmithKline

Completed

A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

Cancer

Australia, United States, United Kingdom
Hoffmann-La Roche

Completed

Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies

Malignant Melanoma, Cancer

Hungary

3

Subscribe